Compare BHF & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHF | CDNA |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | 2018 | 2007 |
| Metric | BHF | CDNA |
|---|---|---|
| Price | $41.16 | $77.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $60.83 | ★ $93.50 |
| AVG Volume (30 Days) | 720.3K | ★ 1.4M |
| Earning Date | 11-17-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.06 | N/A |
| EPS | ★ 2.84 | 2.45 |
| Revenue | ★ $6,766,000,000.00 | $48,324,000.00 |
| Revenue This Year | $24.39 | $38.20 |
| Revenue Next Year | $1.79 | $9.07 |
| P/E Ratio | ★ $14.95 | $35.04 |
| Revenue Growth | ★ 43.23 | 18.93 |
| 52 Week Low | $41.98 | $14.72 |
| 52 Week High | $66.80 | $90.87 |
| Indicator | BHF | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 22.31 | 73.25 |
| Support Level | N/A | $17.30 |
| Resistance Level | $63.55 | N/A |
| Average True Range (ATR) | 1.32 | 4.79 |
| MACD | -0.23 | 1.62 |
| Stochastic Oscillator | 6.54 | 82.12 |
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are: Annuities, that derives majority of the revenue, includes variable, fixed, index-linked, and income annuities; The life segment includes variable, term, universal, and whole life policies; The Run-off segment consists of products that are no longer actively sold and are separately managed, including ULSG, structured settlements, pension risk transfer contracts, certain company-owned life insurance policies and certain funding agreements; and The Corporate & Other segment consists of activities related to funding agreements associated with the company.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.